Clinical trials: Apixaban
Venous Thromboembolism
Apixaban for the Acute Treatment of Venous Thromboembolism in Children
To assess the safety and descriptive efficacy of apixaban in pediatric subjects requiring anticoagulation for the treatment of a VTE.
- Trial name
- NCT02464969
- Testing
- Apixaban, Standard of Care
- Where
- 128 sites in United States, Australia and 11 more
- Volunteers
- 229 people
- Sponsor
- Bristol-Myers Squibb
Atrial Fibrillation (AF)
Pacing of Left Bundle Branch Area and Atroventricular Node ablatIon in Patients With Symptomatic Atrial Fibrillation
This study aimed to compare the clinical outcomes of left bundle branch area pacing combined with atrioventricular node ablation and pharmacologic treatment optimized according to guidelines in patients with symptomatic atrial…
- Trial name
- PALLIATE-AF (NCT06699342)
- Testing
- Pacemaker implantation with Left bundle branch area pacing (LBBAP), Atrioventricular node ablation (AVNA), Pharmacologic therapy optimized for Atrial Fibrillation management
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Seoul National University Hospital
Subject Under Anticoagulant
Prospective Real-world Registry Describing Treatment Regimens
This study is to describe the initial anti-thrombotic treatment strategy prescribed to the AF patient population undergoing PCI by using drug class description.
- Trial name
- PRAETORIAN (NCT03942913)
- Testing
- an observational study
- Where
- France
- Volunteers
- 573 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Intracerebral Hemorrhage, Atrial Fibrillation
Avoiding Anticoagulation After IntraCerebral Haemorrhage
Randomised controlled trials (RCTs) demonstrate a substantial benefit from oral anticoagulant drugs for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation (AF).
- Conditions
- Intracerebral Hemorrhage, Atrial Fibrillation, Microhaemorrhage
- Trial name
- A3ICH (NCT03243175)
- Testing
- Apixaban 5 MG, left atrial appendage closure
- Where
- 3 sites in France
- Volunteers
- 300 people
- Sponsor
- University Hospital, Lille
Direct Oral Anticoagulant, Hemmorhage
Evaluation of the Relationship Between Muscle Mass Measured by Bioelectrical Impedance Analysis and the Risk of Hemorrhagic Events Under Direct Oral Anticoagulants in the Elderly
This study aims to assess whether reduced muscle mass is associated with an increased risk of bleeding in the elderly receiving direct oral anticoagulant therapy.
- Conditions
- Direct Oral Anticoagulant, Hemmorhage, Elderly, Muscle Mass
- Trial name
- SARCORRHAGED (NCT07173075)
- Testing
- impedancemetry
- Where
- France
- Volunteers
- 110 people
- Sponsor
- University Hospital, Clermont-Ferrand
Atrial Fibrillation
Evaluation of Safety and Effectiveness on Oral Anticoagulants
This study is to compare the risk of major bleeding among oral anticoagulant (OAC)-naïve non-valvular atrial fibrillation (NVAF) patients initiating treatment
- Trial name
- RCR-OAC (NCT03765242)
- Testing
- Non-Interventional
- Where
- Japan
- Volunteers
- 12,354 people
- Sponsor
- Bristol-Myers Squibb
Subdural Hematoma, Atrial Fibrillation
Anticoagulation Therapy Timing in Atrial Fibrillation After Acute and Chronic Subdural Hematoma
Subdural hematoma (SDH) is a common disorder that typically results from head trauma and has increased in prevalence in recent decades.
- Trial name
- ATTAACH (NCT05472766)
- Testing
- Direct Acting Oral Anticoagulant starting at Day 30, Direct Acting Oral Anticoagulant starting at Day 90
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- Sunnybrook Health Sciences Centre
Non-valvular Atrial Fibrillation
Safety and Effectiveness of Apixaban Compared to Warfarin in Patients With Non-valvular Atrial Fibrillation (a Type of Irregular Heart Rhythm) at Higher Chance of Bleeding
The purpose of this study is to compare effectiveness and safety of warfarin and apixaban among non-valvular atrial fibrillation (NVAF) patients at higher chance of bleeding using a Japanese nation-wide administrative claims…
- Trial name
- NCT05471505
- Where
- Japan
- Volunteers
- 120,722 people
- Sponsor
- Pfizer
Postpartum, DVT Prophylaxis
Apixaban Versus Enoxaparin for Postpartum Venous Thromboembolism Prophylaxis
The purpose of this study is to compare the use of oral apixaban to subcutaneous enoxaparin for venous thromboembolism (VTE) prophylaxis in postpartum women at high risk for VTE.
- Trial name
- NCT07716332
- Testing
- Apixaban, Enoxaparin
- Volunteers
- 150 people
- Sponsor
- Ron Beloosesky MD
Bleeding Post Cardiac Surgery, Indication for Anticoagulation
The Direct Oral Anticoagulation Versus Vitamin K Antagonist After Cardiac Surgery Trial
The DANCE Trial is a multi-centre, randomized controlled trial comparing the safety of direct oral anticoagulants (DOAC) versus vitamin K antagonists (VKA) in the early period (30 days) after cardiac surgery in patients with…
- Trial name
- DANCE (NCT04284839)
- Testing
- DOAC, VKA
- Where
- 19 sites in Australia, Canada and 1 more
- Volunteers
- 3,500 people
- Sponsor
- Population Health Research Institute
Persistent Atrial Fibrillation
Comparison of Brain Perfusion in Rhythm Control and Rate Control of Persistent Atrial Fibrillation
Atrial fibrillation (AF) is associated with impaired cognitive function (CogF) and/or dementia, but it is unclear whether rhythm control of AF improves CogF or brain perfusion.
- Trial name
- NCT02633774
- Testing
- Propafenone, Apixaban
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Yonsei University
Coagulation
Clinical Performance Evaluation of Native Whole Blood Samples of Patients on DOACs With the Perosphere ClotChek™
The Perosphere ClotChek™ system consists of a hand-held, battery-operated blood coagulation instrument and disposable test cuvettes for use at the point-of-care (POC).
- Trial name
- NCT07012291
- Testing
- Whole Blood Clotting Time
- Where
- 4 sites in United States
- Volunteers
- 150 people
- Sponsor
- Perosphere Technologies Inc.
Covid19
Evolution of COVID-19 in Anticoagulated or Antiaggregated Patients (CORONA Study)
CORONA is a retrospective, observational, one center study to investigate the clinical evolution (in terms of survival and thromboembolic complications) of patients on chronic treatment with anticoagulants or antiplatelet agents…
- Trial name
- CORONA (NCT04518735)
- Testing
- Antithrombotic Therapy (anticoagulant and/or antiplatelet) before admission for Covid19
- Where
- Spain
- Volunteers
- 1,707 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Atrial Fibrillation
Preventing Stroke, Premature Death and Cognitive Decline in a Broader Community of Patients With Atrial Fibrillation
The DaRe2 approach (healthcare Data for pragmatic clinical Research in the NHS - primary 2 secondary) is designed to operationalise efficient, nationwide, primary care approaches for randomised trials embedded within the UK…
- Trial name
- DaRe2THINK (NCT04700826)
- Testing
- Direct Oral Anticoagulants
- Where
- United Kingdom
- Volunteers
- 3,000 people
- Sponsor
- University of Birmingham
Glioblastoma, Astrocytoma
Venous Thromboembolism Prevention in Outpatients With Glioma
This is an open label study of apixaban for venous thromboembolism prevention in patients with newly diagnosed grade 4 glioma.
- Conditions
- Glioblastoma, Astrocytoma, Venous Thromboembolism
- Trial name
- VTE-POG (NCT05683808)
- Testing
- Apixaban
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Vermont Medical Center
Atrial Fibrillation and Flutter
Direct Oral Anticoagulants Pharmacodynamics in Octogenarian Patients With Atrial Fibrillation
Background: The incidence of atrial fibrillation(AF) increases substantially with age and it is estimated that more than one third of AF patients are octogenarians.
- Trial name
- NCT02623049
- Testing
- New oral anticoagulant pharmacodynamic analysis (blood level assesment)
- Where
- 2 sites in Israel
- Volunteers
- 150 people
- Sponsor
- Rabin Medical Center
Atrial Fibrillation, Acute Coronary Syndrome
Triple vs. Dual Therapy
Background: The acute coronary syndrome (ACS) is a complication of coronary artery disease (CAD) and associated with increased mortality.
- Trial name
- NCT02080858
- Testing
- Ticagrelor + Apixaban + ASA, Ticagrelor + Apixaban
- Where
- Austria
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Cancer-associated Thrombosis, Venous Thromboembolism
The Gynecological Cancer Associated Thrombosis (GynCAT) Study
GynCAT is a prospective cohort study that will be conducted on female patients with gynecologic malignancies scheduled for systemic antineoplastic treatment, aiming at development and validation of a Risk Assessment Model (RAM)…
- Conditions
- Cancer-associated Thrombosis, Venous Thromboembolism, Gynecologic Cancer, Ovarian Cancer
- Trial name
- GynCAT (NCT06284343)
- Testing
- Anticoagulant
- Where
- Italy
- Volunteers
- 1,800 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Atrial Fibrillation (AF)
Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation
The DESTINATION Study investigates whether anticoagulation therapy is necessary after successful catheter ablation (CA) for atrial fibrillation (AF).
- Trial name
- DESTINATION (NCT06615596)
- Testing
- discontinue anticoagulation therapy, Anticoagulant drugs, Catheter Ablation
- Where
- 12 sites in United States, China
- Volunteers
- 3,160 people
- Sponsor
- China National Center for Cardiovascular Diseases
Deep Vein Thrombosis, Pulmonary Embolism
Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism
Design: U.S.-based, single-center, randomized placebo-controlled trial. Brief Treatment Description: Low-intensity apixaban (2.5mg twice daily) for extended-duration secondary prevention of VTE after initial treatment for…
- Conditions
- Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism
- Trial name
- HI-PRO (NCT04168203)
- Testing
- Apixaban 2.5 MG
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Brigham and Women's Hospital